Dr. Wang Yinxiang is currently Chairman and CEO of Jacobio.
Dr. Wang Yinxiang has more than 30 years of experience oncology research. He once led the research and marketing of icotinib hydrochloride (Conmana®, the first targeted anti-tumor drug in China). Before he established Jacobio, he served as President and CSO of Betta Pharmaceuticals (300558.SZ).
Dr. Wang Yinxiang earned his Ph.D. from the University of Arkansas for Medical Sciences, USA. After that, he was engaged in postdoctoral research in the Department of Molecular Biophysics and Biochemistry, Yale University. Now, he is the vice chairman of the Anti-tumor Drug Professional Committee of the Chinese Pharmaceutical Association, he was chairman of the Drug R&D Specialty Committee of the China Pharmaceutical Innovation and Research Development Association (PHIRDA).
Wang Xiaojie is currently the President of Administration of Jacobio and also serves as Executive Director of Board.
Fully committed to Jacobio’s strategy of targeting the global market, Wang Xiaojie is in charge of the operation and management of supporting departments of the company, including human resources, finance, legal affairs, government affairs and investor relations. She has more than 20 years of leadership experience in the pharmaceutical industry and previously served as Vice President at Betta Pharmaceuticals (300558.SZ).
Wang Xiaojie graduated from Dalian Polytechnic University with a bachelor’s degree and completed an executive MBA program at Peking University.
Hu Yunyan is currently Executive Vice President of Jacobio and also serves as Executive Director of Board.
Hu Yunyan is in charge of the company’s quality management system, responsible for quality and regulatory compliance work, and supervises regulatory compliance in laboratory, clinical, pharmacovigilance, and production.
She has more than 20 years of practical experience in the pharmaceutical industry. Before joining Jacobio, she worked at Betta Pharmaceuticals (300558.SZ) and led the chemistry, manufacturing, and controls (CMC) work for icotinib hydrochloride (Conmana®, the first targeted anti-tumor drug in China). Based on her outstanding contributions, she was granted the title of “Beijing Model Worker” in 2015.
Hu Yunyan earned a master’s degree in analytical chemistry from the Lanzhou Institute of Chemical Physics of the Chinese Academy of Sciences.
Dr. Andrea Wang-Gillam is the Chief Medical Officer and Executive Vice President at Jacobio. She is in charge of global clinical development and operations of Jacobio’s R&D projects.
An expert in gastrointestinal oncology, Dr. Wang-Gillam has more than ten years of research experience in clinical and translational oncology. Born into a family of doctors, she is passionate about prospective research into cancer. Prior to joining Jacobio, she was an oncologist, Director of Gastrointestinal Oncology, and Director of the Early Clinical Trial Center at Washington University School of Medicine in St. Louis, U.S., and served as Principal Investigator (PI) in more than 60 clinical trials. She led the NAPOLI-1 Phase III clinical study of irinotecan liposome injection (Onivyde®), which was later approved for commercialisation in the U.S., Europe, and across Asia.
Dr. Wang-Gillam obtained her M.D. and Ph.D. in molecular biology from the University of Arkansas for Medical Sciences, U.S. She has published more than 90 peer-reviewed papers and been the lead author in multiple papers published in international top-tier journals such as The Lancet, The Lancet Oncology, and the Journal of Clinical Oncology.
Dr. Long Wei is Jacobio’s Executive Vice President of Preclinical R&D.
Dr. Long leads preclinical work related to target evaluation, molecular design, chemistry, manufacturing, and controls (CMC), and patent protection for the company. He has more than 15 years of front-line drug development experience.
Prior to joining Jacobio, Dr. Long worked at Betta Pharmaceuticals (300558.SZ), where he led preclinical studies of multiple national Class I novel drugs and was responsible for process development and manufacturing technology transfers of the national Class I new drug icotinib hydrochloride (Conmana®).
After joining Jacobio, he led the team that completed the molecule design and preclinical research of several key projects, including SHP2 inhibitors, KRAS inhibitors, and more.
Dr. Long earned a Ph.D. in organic chemistry from Beijing University of Technology and completed postdoctoral research in medical immunology at Peking University.
Wang Yanping is currently the Senior Vice President of the Pharmacology Department at Jacobio.
Wang Yanping is responsible for preclinical pharmacology, pharmacokinetics and toxicology studies. Under her leadership, her team has completed preclinical studies of multiple innovative drugs that have been granted investigational new drug (IND) approvals in both China and the U.S.
Having worked for more than 15 years in the research and development of new drugs, Wang Yanping has extensive experience in the evaluation of novel drugs, preclinical development and investigational new drug (IND) submissions. Prior to joining Jacobio, she was the Director of the Pharmacology Department of Betta Pharmaceuticals’s R&D Center.
Wang Yanping holds a bachelor’s degree in biology and a master’s degree in physiology from Nanjing University. She was once granted the title of The 23rd Beijing Outstanding Young Engineer.
Ding Yuli, Senior Vice President of Clinical Development at Jacobio, built clinical study teams in China and the United States, participates in strategy formulation for clinical development and is responsible for the implementation, operation, and management of clinical studies.
Ding Yuli has more than 20 years of clinical development experience. Prior to working for Jacobio, she worked for Janssen Pharmaceuticals, GlaxoSmithKline and Sihuan Pharmaceuticals. She has led teams that have completed registrational studies related to nearly 20 projects in both international multi-center and domestic studies. During her tenure at Janssen, she won the President's Award and the Global Leadership Award multiple times and spent time studying and working at Janssen's headquarters in Belgium.
Ding Yuli hold a bachlor's degree from China Phamaceutical University, and a master’s degree in pharmacology Inner Mongolia Medical University.
Dr. Wang Haijun is now Senior Vice President at Jacobio, responsible for the design and management of the company’s information system.
Dr. Wang Haijun worked abroad for more than 20 years. Prior to joining Jacobio, he was an assistant professor in the Department of Family and Community Medicine at Baylor College of Medicine in the U.S, where he conducted medical information management, data statistical analysis and health service research .
Dr. Wang Haijun holds a doctoral degree in epidemiology and health statistics from the Chinese Center for Disease Control and Prevention (CDC), as well as a master’s degree in chemistry from Lamar University, U.S., and a master’s degree in public health from Beijing Medical University (now Peking University Health Science Center).
Dr. LI Qiao is currently Vice President of Biostatistics and Data Science at Jacobio, responsible for biostatistics, statistical programming and data management in drug clinical studies.
He has extensive experience in drug development and management. He once worked as Head of Biostatistics and Programming at Astellas (China), Head of Biostatistics at Novo Nordisk (China), and Senior Scientist in the Department of Biostatistics and Research Decision Sciences at Merck Sharp & Dohme.
Dr. LI Qiao obtained his Ph.D. in computing sciences from the University of East Anglia, UK, and then worked in postdoctoral research at Imperial College London. He is a member of the Clinical Trial Research Specialty Committee of the China Pharmaceutical Innovation and Research Development Association and a member of the Expert Committee on Biostatistics of the Chinese Society of Clinical Oncology (CSCO).
Dr. Kang Jian is Vice President of Intellectual Property (IP) at Jacobio.
She has been focused on intellectual property protection in the life sciences field since 2004. Since joining Jacobio in 2020, she has led a team of in-house professionals to protect the company’s R&D and business.
Dr. Kang is a licensed patent attorney and patent litigator recognized by the All-China Patent Attorneys Association. Prior to joining Jacobio, she worked at the Sydney office of Spruson & Ferguson as a partner for Greater China and in the intellectual property department of Bayer (China).
Dr. Kang earned an M.D. degree from Peking Union Medical College, and a master of laws (LL.M.) from China University of Political Science and Law. She is a qualified patent attorney and lawyer in mainland China. She has visited and interned at the U.S. Court of Appeals for the Federal Circuit (CAFC), was a member of the All-China Patent Attorneys Association (ACPAA), the American Intellectual Property Law Association (AIPLA), and the Association of University Technology Managers (AUTM).
Dr. Fan Bin is currently Vice President of Clinical Pharmacology at Jacobio, where he is responsible for establishing the company’s clinical pharmacology, quantitative pharmacology and bioassay platforms.
Dr. Fan has more than 20 years of experience working in pharmaceutical companies in the U.S. Prior to joining Jacobio, Dr. Fan worked at Vertex Pharmaceuticals (NASDAQ:VERX) and Agios Pharmaceuticals (NASDAQ:AGIO). He led and participated in the clinical pharmacology and drug metabolism of IDHIFA® and Tibosovo®.
Dr. Fan holds a bachelor’s degree in pharmacology from Shanghai Medical University (now Shanghai Medical College of Fudan University), and a Ph.D. in pharmaceutical and biomedical sciences from the University of Georgia, US.
Cao Hong is currently Vice President of chemistry, manufacturing, and controls (CMC) at Jacobio.
She is responsible for the manufacturing process, impurity studies, quality studies and stability studies of more than 10 ongoing projects. Prior to joining Jacobio, Cao Hong was the Director of the Analytical Department of Betta Pharmaceuticals’s R&D Center. During her tenure, she was responsible for the analysis and development of icotinib hydrochloride (Conmana®). She has worked in drug analysis and development for 20 years, and has accumulated extensive experience in quality research and CMC applications of novel drugs.
Cao Hong earned her master’s degree in analytical chemistry from Jilin University and a bachelor's degree in chemistry from the Lanzhou Institute of Chemical Physics of the Chinese Academy of Sciences.
YANG Tao is currently Vice President of Human Resources at Jacobio.
YANG Tao is responsible for promoting the organizational development, construction and implementation of the company. She has more than 20 years of working experience in multinational pharmaceutical companies. She worked in multiple human resources management positions at Novartis, led the successful implementation of multiple organizational changes and talent development programs. For eight years after 2012, she served as head of human resources for Novartis Oncology (China).
YANG Tao graduated from Beijing Normal College (now Capital Normal University) with a bachelor’s degree.